The following studies have contributed to our Methamphetamine Dependence datasets.
Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068
Investigator: Madhukar Trivedi Release Date: August 2024 View Study in Clinical Trials Network Site Study Objective: The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the combination pharmacotherapy on other...
Study 47 – Ketamine for Methamphetamine Use Disorder (KMD); CTN-0132
Principal Investigator: Madhukar H. Trivedi, M.D. Co-Investigators: Manish K. Jha, MBBS; Sidarth Wakhlu, M.D., Thomas Carmody, Ph.D. Release Date: TBA Objective: The primary objective of this study will be to assess preliminary efficacy, safety, and feasibility of a course of intravenous (IV) ketamine (compared with IV midazolam) as a treatment for methamphetamine use disorder. Significance/Impact: Effective management for methamphetamine use...